Literature DB >> 11777363

The risk-benefit profile of commonly used herbal therapies: Ginkgo, St. John's Wort, Ginseng, Echinacea, Saw Palmetto, and Kava.

Edzard Ernst1.   

Abstract

Because use of herbal remedies is increasing, a risk-benefit profile of commonly used herbs is needed. This article provides a clinically oriented overview of the efficacy and safety of ginkgo, St. John's wort, ginseng, echinacea, saw palmetto, and kava. Wherever possible, assessments are based on systematic reviews of randomized clinical trials. Encouraging data support the efficacy of some of these popular herbal medicinal products, and the potential for doing good seems greater than that for doing harm. The published evidence suggests that ginkgo is of questionable use for memory loss and tinnitus but has some effect on dementia and intermittent claudication. St. John's wort is efficacious for mild to moderate depression, but serious concerns exist about its interactions with several conventional drugs. Well-conducted clinical trials do not support the efficacy of ginseng to treat any condition. Echinacea may be helpful in the treatment or prevention of upper respiratory tract infections, but trial data are not fully convincing. Saw palmetto has been shown in short-term trials to be efficacious in reducing the symptoms of benign prostatic hyperplasia. Kava is an efficacious short-term treatment for anxiety. None of these herbal medicines is free of adverse effects. Because the evidence is incomplete, risk-benefit assessments are not completely reliable, and much knowledge is still lacking.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11777363     DOI: 10.7326/0003-4819-136-1-200201010-00010

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  70 in total

1.  Herbal kava: reports of liver toxicity.

Authors:  Eric Wooltorton
Journal:  CMAJ       Date:  2002-03-19       Impact factor: 8.262

2.  Taking St John's wort during pregnancy.

Authors:  Ran D Goldman; Gideon Koren
Journal:  Can Fam Physician       Date:  2003-01       Impact factor: 3.275

3.  Complementary and alternative medicine use among US adults with common neurological conditions.

Authors:  Rebecca Erwin Wells; Russell S Phillips; Steven C Schachter; Ellen P McCarthy
Journal:  J Neurol       Date:  2010-06-11       Impact factor: 4.849

4.  Is it time for oncologists to modify their laissez-faire attitude toward alternative/complementary 'drug therapy'?

Authors:  Maurie Markman
Journal:  Curr Oncol Rep       Date:  2004-01       Impact factor: 5.075

5.  Sale of kava extract in some health food stores.

Authors:  Edward Mills; Rana Singh; Cory Ross; Edzard Ernst; Joel G Ray
Journal:  CMAJ       Date:  2003-11-25       Impact factor: 8.262

Review 6.  Benefit-risk analysis : a brief review and proposed quantitative approaches.

Authors:  William L Holden
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

Review 7.  Is the increasing use of evidence-based pharmacotherapy causing the renaissance of complementary medicine?

Authors:  Samuel Vozeh
Journal:  Br J Clin Pharmacol       Date:  2003-09       Impact factor: 4.335

Review 8.  Utility of nutraceutical products marketed for cognitive and memory enhancement.

Authors:  Graham J McDougall; Vonnette Austin-Wells; Teena Zimmerman
Journal:  J Holist Nurs       Date:  2005-12

Review 9.  Treatment of resistant hypertension.

Authors:  Sandra J Taler
Journal:  Curr Hypertens Rep       Date:  2005-10       Impact factor: 5.369

Review 10.  Drug treatment of intermittent claudication.

Authors:  Douglas Jacoby; Emile R Mohler
Journal:  Drugs       Date:  2004       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.